EichorEICHOR
Location: Colorado Springs Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Colorado Springs

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · Pfizer · NCT05020236Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Merck Sharp & Dohme LLC · NCT06393374Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Penrose-Saint Francis Healthcare · NRG Oncology · NCT05174169Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Phase 3 · Skylight Health Research - Colorado Springs · Eli Lilly and Company · NCT07353931The Healthy Families Bright Futures Program
NA · University of Colorado Colorado Springs · University of Colorado, Colorado Springs · NCT06309134ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Penrose-Saint Francis Healthcare · Alliance for Clinical Trials in Oncology · NCT06876714Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Penrose-Saint Francis Healthcare · National Cancer Institute (NCI) · NCT04269902Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Penrose-Saint Francis Healthcare · Canadian Cancer Trials Group · NCT06592924A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central
Phase 2/Phase 3 · Colorado Springs, Colorado · Centessa Pharmaceuticals (UK) Limited · NCT07598708Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Penrose-Saint Francis Healthcare · Alliance for Clinical Trials in Oncology · NCT04242095A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Phase 3 · Colorado Springs Neurological Associates · argenx · NCT07091630WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase 2 · Mediar Therapeutics · NCT06967805An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ
Phase 3 · Peak Gastroenterology Associates - Colorado Springs-Site Num · Sanofi · NCT07184931A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Phase 2 · Asthma & Allergy Associates - Colorado Springs · Eli Lilly and Company · NCT07219173Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associate
Phase 3 · Local Institution - 1014 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT05980949Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NA · Penrose-Saint Francis Healthcare · Eastern Cooperative Oncology Group · NCT05108298Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult
Phase 3 · Rocky Mountain Cancer Centers, LLP · Pfizer · NCT07222800Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Penrose-Saint Francis Healthcare · ECOG-ACRIN Cancer Research Group · NCT04566328Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With
Phase 3 · UCHealth Memorial Hospital Central · National Cancer Institute (NCI) · NCT07198074A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · Prelude Therapeutics · NCT07469891Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NA · Penrose-Saint Francis Healthcare · NRG Oncology · NCT05080673A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Tr
Phase 3 · Merck Sharp & Dohme LLC · NCT06312176Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Penrose-Saint Francis Healthcare · SWOG Cancer Research Network · NCT04205968Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head
Phase 2 · Penrose-Saint Francis Healthcare · ECOG-ACRIN Cancer Research Group · NCT02734537Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Phase 3 · Colorado Springs Neurological Associates · Pfizer · NCT05156398S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · Penrose-Saint Francis Healthcare · SWOG Cancer Research Network · NCT03418961Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3 · Novartis Pharmaceuticals · NCT05827081A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Phase 3 · Colorado Springs Neurological Associates · argenx · NCT06920004S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · Penrose-Saint Francis Healthcare · SWOG Cancer Research Network · NCT03723928Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT06475989
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.